Canopus Biopharma (CBIA) Stock Statistics & Valuation Metrics
Total Valuation
Canopus Biopharma has a market cap or net worth of $4,551.00. The enterprise value is $461.13B.
- Market Cap
- $4,551.00
- Enterprise Value
- $461.13B
Share Statistics
Canopus Biopharma has 4,550,711,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,550,711,000
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Canopus Biopharma’s return on equity (ROE) is 57.57 and return on invested capital (ROIC) is 25400.66%.
- Return on Equity (ROE)
- 57.57
- Return on Assets (ROA)
- -181.43
- Return on Invested Capital (ROIC)
- 25400.66%
- Return on Capital Employed (ROCE)
- 57.56
- Revenue Per Employee
- 0
- Profits Per Employee
- -10.62K
- Employee Count
- 72
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Canopus Biopharma is -0.01. Canopus Biopharma’s PEG ratio is -0.00.
- PE Ratio
- -0.01
- PS Ratio
- 0.00
- PB Ratio
- -0.83
- Price to FCF
- -73.64
- Price to Operating Cash Flow
- -1.77
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Canopus Biopharma had revenue of 0 and earned -764.71K in profits. Earnings per share was -0.01.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -764.56K
- Pretax Income
- -764.71K
- Net Income
- -764.71K
- EBITDA
- -764.56K
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -159.18K and capital expenditures 0, giving a free cash flow of -159.18K billion.
- Operating Cash Flow
- -159.18K
- Free Cash Flow
- -159.18K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
Canopus Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.36%
- Earnings Yield
- -6975.94%
Stock Price Statistics
- Beta
- -37.83
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
Canopus Biopharma as a current ratio of 0.24, with Debt / Equity ratio of -77.34%
- Current Ratio
- 0.24
- Quick Ratio
- 0.24
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.01
- Interest Coverage Ratio
- -5272.83
Taxes
In the past 12 months, Canopus Biopharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Canopus Biopharma EV to EBITDA ratio is -0.60, with an EV/FCF ratio of -74.62.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.60
- EV to Free Cash Flow
- -74.62
- EV to Operating Cash Flow
- -74.56
Balance Sheet
Canopus Biopharma has $6,153.00 in cash and marketable securities with $183.88K in debt, giving a net cash position of -$177.73K billion.
- Cash & Marketable Securities
- $6,153.00
- Total Debt
- $183.88K
- Net Cash
- -$177.73K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- $0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Canopus Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
